Oct 23, 2013
Global Green, Inc.’s Salmonella Vaccine Could Meet the Eight Point Ideal Vaccine Criteria Outlined at Poultry Science Outlook Seminar
Tallahassee, Fla – Global Green, Inc. (OTCBB:GOGC), a green bio-pharmaceutical company, today announced that its patented Salmonella vaccine for poultry, Salmogenics, could meet all ideal vaccine criteria as outlined by Professor Paul Barrow at the recent “Poultry Science Outlook” seminar in Bangkok, Thailand, sponsored by the World’s Poultry Science Association.
The Poultry Site reported in June 2013 that Professor Barrow of the School of Veterinary Medicine and Science at the University of Nottingham, United Kingdom, addressed Vaccinating Poultry as a Means of Salmonella Control. Salmonella remains a problem in intensive poultry rearing, in the tropics and in free-range systems. He explained that there is a range of approaches to its control including bio security, antibiotics, competitive exclusion, breeding for genetic resistance and vaccination.
Injected in-ovo, Global Green’s Salmogenics vaccine improves the immune system’s defense against Salmonella and other intestinal bacteria, supporting the health and welfare of broiler chickens, and provides a healthier source of protein for humans. Salmogenics’ testing showed a stronger immune system against Salmonella, and the data collected suggest that this vaccine could produce increased weight gain and reduced mortality in poultry. Salmogenics could also lessen the need for use of antibiotics applied for the control of Salmonella, an essential benefit to both the poultry industry and, ultimately, consumers.
Salmogenics could meet all eight of the criteria that Professor Barrow outlined for an ideal vaccine. Those eight criteria are included in bold below followed by Global Green’s comments on how Salmogenics meets those criteria:
Criteria point 1. Strong protection against both fecal excretion and systemic infection (chicks and ovarian)
Global Green comment: Salmogenics protects broilers challenged with live Salmonella right before they reach the final consumers, and the vaccinated broilers have shown approximately five times less Salmonella than the non-vaccinated broilers.
Criteria point 2. Stable avirulence in Man
Global Green comment: The germs in our green vaccine are dead. They are killed by heat and are not virulent (dangerous or harmful) to any species.
Criteria point 3. Avirulent for chickens, without adversely impacting growth rate
Global Green comment: The germs in our green vaccine are dead. They are killed by heat and are not virulent to any species. Trials show that at the end of the growing cycle, the vaccinated broilers’ growth rate could be higher, one of the trials showed broilers weighing an average 0.1296 pounds more than the non-vaccinated broilers.
Criteria point 4. Long lasting protection
Global Green comment: Vaccinated broilers showed protection against Salmonella until broilers are 45 days old, so the broilers are protected until they are processed for the consumer.
Criteria point 5. Protection against many serotypes
Global Green comment: Salmogenics protects against the four types of Salmonella included in the vaccine and is likely to protect against an undetermined larger number of similar Salmonella of other serotypes.
Criteria point 6. Easily administered
Global Green comment: Salmogenics’ in-ovo administration is automatized
Criteria point 7. Easy to differentiate from the field strain by culture or serology
Global Green comment: The strains in the Salmogenics vaccine have well-defined and known serological characteristics.
Criteria point 8. Compatible with other control measures
Global Green comment: Salmogenics is compatible with other control measures and appears to help the efficacy of other measures.
“The global burden of Salmonella is extraordinary and unacceptable. We are proud that we have developed a vaccine to help combat Salmonella in poultry and are pleased that our vaccine could meet the ideal vaccine criteria outlined by Mr. Barrow.”
About Global Green, Inc.
Global Green, Inc. is a green bio-pharmaceutical company committed to identifying technology platforms and commercializing vaccines that contain natural organisms that are not genetically modified, utilizing pharmaceutical standards without the use of mercury. For more information, visit www.globalgreeninc.com.
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that such forward-looking statements involve risks and uncertainties which include, among others, the inherent uncertainties associated with smaller reporting companies including, without limitation, other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.